Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus.
clinical trials
cutaneous lupus erythematosus
systemic lupus erythematosus
Journal
F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320
Informations de publication
Date de publication:
2019
2019
Historique:
accepted:
19
03
2019
entrez:
16
4
2019
pubmed:
16
4
2019
medline:
12
5
2020
Statut:
epublish
Résumé
Cutaneous lupus erythematosus (CLE) is an autoimmune disease that can be associated with systemic lupus erythematosus (SLE) symptoms. The pathogenesis of both CLE and SLE is multifactorial, involving genetic susceptibility, environmental factors, and innate and adaptive immune responses. Despite the efficacy of current medications, many patients remain refractory, highlighting the necessity for new treatment options. Unfortunately, owing to challenges related in part to trial design and disease heterogeneity, only one new biologic in the last 50 years has been approved by the US Food and Drug Administration for the treatment of SLE. Thus, although SLE and CLE have a similar pathogenesis, patients with CLE who do not meet criteria for SLE cannot benefit from this advancement. This article discusses the recent trials and emphasizes the need to include patients with single-organ lupus, such as CLE, in SLE trials.
Identifiants
pubmed: 30984372
doi: 10.12688/f1000research.17787.1
pmc: PMC6436187
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR071653
Pays : United States
Déclaration de conflit d'intérêts
Competing interests: The authors are employed by the University of Pennsylvania, which owns the copyright for the CLASI. No competing interests were disclosed.Competing interests: Participated on Advisory boards for AstraZeneca. No competing interests were disclosed.
Références
Lupus. 2002;11(2):71-81
pubmed: 11958581
Best Pract Res Clin Rheumatol. 2002 Apr;16(2):245-64
pubmed: 12041952
Arch Dermatol. 2003 Jan;139(1):50-4
pubmed: 12533164
Clin Rev Allergy Immunol. 2003 Aug;25(1):3-12
pubmed: 12794256
Br J Dermatol. 2007 Jun;156(6):1321-7
pubmed: 17408395
Arch Dermatol. 2009 Mar;145(3):303-6
pubmed: 19289762
J Am Acad Dermatol. 2011 May;64(5):849-58
pubmed: 21397983
Nat Rev Drug Discov. 2011 May;10(5):335-6
pubmed: 21532557
Br J Dermatol. 2011 Jun;164(6):1335-41
pubmed: 21574972
J Am Acad Dermatol. 2011 Oct;65(4):717-721.e2
pubmed: 21641078
Br J Dermatol. 2012 Mar;166(3):616-23
pubmed: 21999437
Arthritis Rheum. 2011 Dec;63(12):3918-30
pubmed: 22127708
Arthritis Care Res (Hoboken). 2012 May;64(5):704-12
pubmed: 22190480
Br J Dermatol. 2012 May;166(5):971-5
pubmed: 22242767
Int J Rheum Dis. 2012 Feb;15(1):62-8
pubmed: 22324948
Ann Rheum Dis. 2012 Nov;71(11):1833-8
pubmed: 22550315
Arthritis Rheum. 2012 Aug;64(8):2677-86
pubmed: 22553077
Mod Rheumatol. 2013 Mar;23(2):318-22
pubmed: 22581095
Arthritis Res Ther. 2012 Dec 07;14(6):R265
pubmed: 23217273
Actas Dermosifiliogr. 2013 Nov;104(9):800-6
pubmed: 23787361
Best Pract Res Clin Rheumatol. 2013 Jun;27(3):391-404
pubmed: 24238695
Br J Haematol. 2014 Mar;164(6):811-21
pubmed: 24328678
J Am Acad Dermatol. 2014 Mar;70(3):583-4
pubmed: 24528907
J Dermatolog Treat. 2015 Apr;26(2):173-7
pubmed: 24731053
Arthritis Care Res (Hoboken). 2015 May;67(6):817-28
pubmed: 25369985
J Invest Dermatol. 2015 Jan;135(1):7-12
pubmed: 25501376
Cytokine. 2015 Jun;73(2):326-34
pubmed: 25767072
Lupus Sci Med. 2015 Mar 26;2(1):e000085
pubmed: 25861460
Dermatol Reports. 2015 Mar 16;7(1):5804
pubmed: 25918617
Am J Clin Dermatol. 2016 Apr;17(2):135-46
pubmed: 26872954
Ann Rheum Dis. 2016 Nov;75(11):1909-1916
pubmed: 27009916
Expert Rev Clin Immunol. 2016 Oct;12(10):1109-21
pubmed: 27249209
Arthritis Care Res (Hoboken). 2017 Jan;69(1):115-123
pubmed: 27390293
J Invest Dermatol. 2017 Jan;137(1):115-122
pubmed: 27646883
Lupus. 2017 Feb;26(2):115-118
pubmed: 27687023
Br J Dermatol. 2017 Jul;177(1):188-196
pubmed: 28112801
Arthritis Rheumatol. 2017 May;69(5):1028-1034
pubmed: 28118537
Arthritis Rheumatol. 2017 Feb;69(2):376-386
pubmed: 28130918
J Am Acad Dermatol. 2017 Aug;77(2):261-267
pubmed: 28606712
J Investig Dermatol Symp Proc. 2017 Oct;18(2):S57-S63
pubmed: 28941496
J Investig Dermatol Symp Proc. 2017 Oct;18(2):S64-S68
pubmed: 28941497
J Am Acad Dermatol. 2018 Feb;78(2):342-350.e4
pubmed: 28989111
Lupus Sci Med. 2018 Mar 23;5(1):e000258
pubmed: 29657738
Lupus. 2018 Aug;27(9):1424-1430
pubmed: 29788808
Ann Rheum Dis. 2018 Nov;77(11):1653-1664
pubmed: 30021804
Lancet. 2018 Jul 21;392(10143):222-231
pubmed: 30043749
J Invest Dermatol. 2019 Feb;139(2):324-332
pubmed: 30227141
J Invest Dermatol. 2019 Feb;139(2):270-276
pubmed: 30243657
J Clin Invest. 2019 Mar 1;129(3):1359-1371
pubmed: 30645203
Int J Dermatol. 1982 Sep;21(7):379-95
pubmed: 6752053
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032